Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.37 |
| ▸ | CCR1 | P32246 | 2/20 | 0.37 |
| ▸ | CCR5 | P51681 | 2/20 | 0.37 |
| ▸ | CCR8 | P51685 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1573687 | 0.86 | KDM4E (0.43) | KDM4EGAALMNAP4HTMCCR1 | |
| (Phenylsulfinyl)Benzene SCHEMBL11889251 | 0.73 | CYP3A4 (0.33) | TDP1ALDH1A1 | |
| SCHEMBL30837415 | 0.73 | — | — | |
| SCHEMBL3254805 | 0.73 | — | — | |
| SCHEMBL20048805 | 0.73 | — | — | |
| SCHEMBL6970710 | 0.73 | — | — | |
| SCHEMBL2759539 | 0.73 | — | — | |
| SCHEMBL29181146 | 0.73 | — | — | |
| (Phenylsulfinyl)Benzene SCHEMBL43199 | 0.72 | TDP1 (0.37) | LMNASMN1; SMN2TDP1EHMT2EHMT1 | |
| SCHEMBL17036660 | 0.72 | KDM4E (0.36) | KDM4EGAALMNAP4HTMCCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118373784-B | One-pot preparation method of 2-aryl benzoxazole and asymmetric sulfoxide | 江苏师范大学 | 2024-09-03 | — | — | CN | disclosed |
| CN-118373784-A | One-pot preparation method of 2-aryl benzoxazole and asymmetric sulfoxide | 江苏师范大学 | 2024-07-23 | — | — | CN | disclosed |
| EP-3784671-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| WO-2019201283-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS, INC. (US) | 2019-10-24 | — | — | WO | disclosed |
| US-20140107343-A1 | INDENOPYRIDINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-17 | — | — | US | disclosed |
| US-20140107343-A1 | INDENOPYRIDINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-17 | — | — | US | disclosed |
| US-8664372-B2 | Process for producing 1,2-trans-glycoside compound | GLYTECH, INC. (JP) | 2014-03-04 | — | — | US | disclosed |
| US-20120232256-A1 | PROCESS FOR PRODUCING 1,2-TRANS-GLYCOSIDE COMPOUND | OTSUKA CHEMICAL CO., LTD. | 2012-09-13 | — | — | US | disclosed |
| US-8212013-B2 | Phenyl 3,4,6-tri-O-benzyl-2-O-(1,1,2,2-tetramethyl-dimethylene phosphonoyl)- beta -D-thioglucopyranoside; inhibits formation of o-ester by-product resulting from the conventional glycosilation reaction of pyranose compounds of 1,2-trans form, affording 1,2-transglycoside compounds with high selectivity | OTSUKA CHEMICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20080177049-A1 | Process for Producing 1,2-Trans-Glycoside Compound | GLYTECH, INC. (JP) | 2008-07-24 | — | — | US | disclosed |
| EP-1849794-A1 | PROCESS FOR PRODUCING 1,2-TRANS-GLYCOSIDE COMPOUND | Otsuka Chemical Co., Ltd. (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232256-A1 | PROCESS FOR PRODUCING 1,2-TRANS-GLYCOSIDE COMPOUND | ADH1C, ADH1A, CYP2E1 | KDM4E 2817/4885GAA 882/4885LMNA 972/4885 |
| US-20080177049-A1 | Process for Producing 1,2-Trans-Glycoside Compound | ADH1C, ADH1A, CYP2E1 | KDM4E 2817/4885GAA 882/4885LMNA 972/4885 |
| US-20140107343-A1 | INDENOPYRIDINE DERIVATIVES | HSD11B1, HSD3B1, HSD11B2 | KDM4E 3419/4885GAA 1535/4885LMNA 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.